AG B3001
Alternative Names: AG-B3001Latest Information Update: 19 Nov 2021
At a glance
- Originator Ahn-Gook Pharmaceutical
- Class Antineoplastics; Biobetters; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Nov 2021 Early research in Cancer in South Korea (Parenteral) (Ahn-Gook Pharmaceutical pipeline, November 2021)